XBiotech Inc.
XBIT
$2.42
-$0.02-0.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.69% | 374.33% | 24.45% | -49.55% | 87.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.70% | 240.13% | -23.49% | -57.66% | 24.85% |
| Operating Income | 53.70% | -240.13% | 23.49% | 57.66% | -24.85% |
| Income Before Tax | 49.74% | -154.20% | -17.98% | 86.74% | -8.80% |
| Income Tax Expenses | 68.97% | 285.37% | 1,033.33% | 212.00% | 16.00% |
| Earnings from Continuing Operations | 49.42% | -155.92% | -19.80% | 86.50% | -8.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.42% | -155.92% | -19.80% | 86.50% | -8.82% |
| EBIT | 53.70% | -240.13% | 23.49% | 57.66% | -24.85% |
| EBITDA | 54.67% | -253.56% | 24.72% | 59.42% | -25.78% |
| EPS Basic | 49.41% | -155.76% | -19.74% | 86.51% | -8.68% |
| Normalized Basic EPS | 49.75% | -159.33% | -17.92% | 86.76% | -8.64% |
| EPS Diluted | 49.41% | -155.76% | -19.74% | 86.51% | -8.68% |
| Normalized Diluted EPS | 49.75% | -159.33% | -17.92% | 86.76% | -8.64% |
| Average Basic Shares Outstanding | 0.00% | 0.07% | 0.05% | 0.10% | 0.14% |
| Average Diluted Shares Outstanding | 0.00% | 0.07% | 0.05% | 0.10% | 0.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |